Skip to main content
. 2024 May 1;16(9):1764. doi: 10.3390/cancers16091764

Figure 2.

Figure 2

Onset of endocrine immune-related adverse events (irAEs), depending on the type of irAEs (A) and the class of immune checkpoint inhibitors (B).